NCT07504588
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07504588
Title Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Group - Fayetteville RECRUITING Fayetteville Arkansas 72703 United States Details
Highlands Oncology Group - Rogers RECRUITING Rogers Arkansas 72758 United States Details
Highlands Oncology Group RECRUITING Springdale Arkansas 72762 United States Details
Kootenai Health - Coeur d'Alene RECRUITING Coeur d'Alene Idaho 83814 United States Details
Kootenai Clinic Cancer Services - Post Falls RECRUITING Post Falls Idaho 83854 United States Details
Kootenai Clinic Cancer Services - Sandpoint RECRUITING Sandpoint Idaho 83864 United States Details
Mercy Hospital Springfield RECRUITING Springfield Missouri 65804 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field